The active U.S. IPO pipeline through late 2026 forms the core driver of market-implied odds, with multiple deals already priced or scheduled before year-end. Recent S-1 activity includes Oura’s $2.1 billion offering (pricing targeted for late September at a $40–44 range) and ADARx Pharmaceuticals’ $350 million deal, while Accelevation Holdings filed terms for a $660 million listing. Broader momentum stems from the post-SpaceX reopening of equity markets, elevated trading volumes in AI-related names, and sustained venture exit pressure. Anthropic’s expected November listing and additional filings in the biotech and insurance sectors further anchor near-term expectations. With roughly three months until 2027, the combination of priced deals, roadshows, and regulatory clearances creates limited scope for a sudden window closure absent a sharp equity-market reversal.
Experimental AI-generated summary referencing Polymarket data. This is not trading advice and plays no role in how this market resolves. · UpdatedDiscord IPO probability collapses amid regulatory delays and market uncertainty
Discord plunges to 11%18%
Discord's expected IPO timeline shifted from early 2026 to mid-2027 due to SEC backlog and valuation concerns, causing market probabilities for a 2026 IPO to collapse and delaying its public debut.

































Beware of external links.
Beware of external links.
Frequently Asked Questions